Last reviewed · How we verify
DHA (Docosahexaenoic Acid)
DHA is an omega-3 polyunsaturated fatty acid that supports neuronal membrane integrity and reduces neuroinflammation in the brain.
DHA is an omega-3 polyunsaturated fatty acid that supports neuronal membrane integrity and reduces neuroinflammation in the brain. Used for Mild to moderate Alzheimer's disease (cognitive decline prevention).
At a glance
| Generic name | DHA (Docosahexaenoic Acid) |
|---|---|
| Also known as | Neuromins |
| Sponsor | Alzheimer's Disease Cooperative Study (ADCS) |
| Drug class | Omega-3 polyunsaturated fatty acid |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
DHA (docosahexaenoic acid) is a 22-carbon omega-3 fatty acid that comprises a significant portion of neuronal cell membranes, particularly in the cerebral cortex and retina. It is hypothesized to reduce cognitive decline in Alzheimer's disease by maintaining synaptic plasticity, reducing amyloid-beta accumulation, and decreasing neuroinflammatory markers. DHA may also enhance mitochondrial function and promote neuroprotection through anti-inflammatory and antioxidant mechanisms.
Approved indications
- Mild to moderate Alzheimer's disease (cognitive decline prevention)
Common side effects
- Gastrointestinal upset
- Fish odor/aftertaste
- Bleeding or bruising (at high doses)
Key clinical trials
- Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia (PHASE2)
- OMEGA - Dietary Intervention - COPD Trial (NA)
- Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids (NA)
- Long-Term Omega-3 and Omega-3 Index >8%: Effects on Physiological Recovery (NA)
- Observing Metabolism of EPA With Consideration of Genetics And Sex (PHASE4)
- Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (NA)
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Evaluation of PKU UP (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DHA (Docosahexaenoic Acid) CI brief — competitive landscape report
- DHA (Docosahexaenoic Acid) updates RSS · CI watch RSS
- Alzheimer's Disease Cooperative Study (ADCS) portfolio CI